Welcome to our dedicated page for Ovid Therapeutics news (Ticker: OVID), a resource for investors and traders seeking the latest updates and insights on Ovid Therapeutics stock.
Ovid Therapeutics Inc (OVID) is a biopharmaceutical innovator developing therapies for rare neurological disorders, with a focus on epilepsy and seizure-related conditions. This page serves as the definitive source for Ovid Therapeutics news, providing investors and stakeholders with timely updates on clinical developments and corporate milestones.
Access official press releases and curated news covering drug development progress, clinical trial results, strategic partnerships, and regulatory updates. Our repository ensures you stay informed about Ovid’s pipeline advancements, including novel candidates targeting Angelman syndrome, fragile X syndrome, and rare epileptic encephalopathies.
Key updates include progress reports on first-in-class therapies, collaborations with industry leaders like Takeda, and insights into Ovid’s scientific approach. Bookmark this page to monitor developments in neurological treatment innovation and make data-driven decisions with direct access to primary source materials.
Ovid Therapeutics (NASDAQ: OVID), a biopharmaceutical company focused on epilepsy treatments, will present at the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, at 11:00 a.m. ET. Management aims to highlight their innovative therapies and ongoing research.
An archived replay of the presentation will be available on their website post-event. Ovid's pipeline includes OV329, a GABA-aminotransferase inhibitor for treatment-resistant seizures, and OV350, targeting epilepsies. Additionally, Ovid is significantly involved in the soticlestat development, currently in Phase 3 trials for Dravet and Lennox-Gastaut syndromes, managed by Takeda. For further information about Ovid's initiatives, visit ovidrx.com.
Ovid Therapeutics (NASDAQ: OVID) provided a business update and 2022 financial results, indicating a cash runway into H1 2025. The company reported a revenue of $1.5 million for 2022, a significant decline from $208.4 million in 2021. This decline was due to a one-time payment from Takeda in 2021. Ovid continues to advance its potential next-generation GABA-aminotransferase inhibitor, OV329, which is undergoing a Phase 1 trial, with results expected in H1 2024. Ovid also highlights ongoing collaborations and cost-cutting measures that have helped reduce operating expenses. The company posted a net loss of $54.2 million for 2022, compared to a net income of $122.8 million in 2021.
FAQ
What is the current stock price of Ovid Therapeutics (OVID)?
What is the market cap of Ovid Therapeutics (OVID)?
